Inhibitory Effects of the Antiangiogenic Agent TNP-470 on Establishment and Growth of Hematogenous Metastasis of Human Pancreatic Carcinoma in SCID Beige Mice in Vivo
Overview
Affiliations
Effects on the liver of the antiangiogenesis agent O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) on hematogenous metastasis of a human pancreatic carcinoma cell line were examined. One million PCI-43 cells, a human pancreas carcinoma cell line, were injected into the spleen of SCID beige mice, then TNP-470 at 30 mg/kg was administered subcutaneously every other day. The mice were killed 6 or 10 weeks thereafter and metastatic nodules in the liver were counted and measured microscopically. Metastases were inhibited and an approximately 10% loss of weight was evident in the TNP-470-administered mice. There was no suppression in maximal size of metastatic colonies in mice given the agent for 6 weeks, while inhibition was apparent in mice given the drug for 10 weeks. Suppression of proliferation and an increase in apoptosis were evident in metastatic nodules in the TNP-470-administered groups, following stainings for proliferative cell nuclear antigen and terminal deoxytransferase-mediated dUTP-biotin nick end-labeling, respectively. TNP-470 inhibited the proliferation of human umbilical vein endothelial cells but not PCI-43 in vitro. TNP-470 did not suppress production of vascular endothelial growth factor by PCI-43 cells. Neovascularization in vivo induced by PCI-43 cells was suppressed in the TNP-470-administered mice, using a diffusion chamber placed in subcutaneous tissues of SCID beige mice. These observations suggest that inhibition of angiogenesis is effective in suppressing establishment and subsequent growth of hematogenous micrometastases of pancreatic adenocarcinoma to the liver.
Fumagillin, a Mycotoxin of : Biosynthesis, Biological Activities, Detection, and Applications.
Guruceaga X, Perez-Cuesta U, Abad-Diaz de Cerio A, Gonzalez O, Alonso R, Hernando F Toxins (Basel). 2019; 12(1).
PMID: 31861936 PMC: 7020470. DOI: 10.3390/toxins12010007.
Cyclooxygenase-2 induces angiogenesis in pancreatic cancer mediated by prostaglandin E.
Xie C, Xu X, Wang X, Wei S, Shao L, Chen J Oncol Lett. 2018; 16(1):940-948.
PMID: 29963167 PMC: 6019925. DOI: 10.3892/ol.2018.8786.
Egawa Y, Saigo C, Kito Y, Moriki T, Takeuchi T PLoS One. 2018; 13(6):e0198940.
PMID: 29879220 PMC: 5991736. DOI: 10.1371/journal.pone.0198940.
In vitro models of pancreatic cancer for translational oncology research.
Feldmann G, Rauenzahn S, Maitra A Expert Opin Drug Discov. 2010; 4(4):429-443.
PMID: 20160967 PMC: 2760831. DOI: 10.1517/17460440902821657.
Biological approaches to therapy of pancreatic cancer.
Wong H, Lemoine N Pancreatology. 2008; 8(4-5):431-61.
PMID: 18724071 PMC: 2882228. DOI: 10.1159/000151536.